Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
104 hedge funds and large institutions have $929M invested in Revance Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 17 reducing their positions, and 6 closing their positions.
417% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 6
165% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 17
117% more call options, than puts
Call options by funds: $5.64M | Put options by funds: $2.59M
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
44% more capital invested
Capital invested by funds: $644M → $929M (+$285M)
32% more funds holding
Funds holding: 79 → 104 (+25)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$53.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$15M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$14.2M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$2.33M |
| 2 |
Goldman Sachs
New York
|
-$2.28M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$2.27M |
| 4 |
Millennium Management
New York
|
-$2.04M |
| 5 |
Fidelity International
Hamilton,
Bermuda
|
-$1.31M |
RVNC Hedge Fund Activity: Q4 2015 in Review
104 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2015, worth a combined $929M — up 44% from $644M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new RVNC positions and 6 closed out — a net gain of 25 holders — while 45 added to existing stakes and 17 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $53.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.33M sold.
- 104 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2015, up from 79 in Q3 2015.
- Funds reported $929M of Revance Therapeutics, Inc. stock for Q4 2015, up 44% quarter-over-quarter.
- 31 funds opened new Revance Therapeutics, Inc. positions in Q4 2015 and 6 closed out, a net change of +25 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2015 was JP Morgan Chase, an estimated $53.4M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2015 was Jennison Associates, an estimated $2.33M sold.
Based on aggregated 13F filings for Q4 2015.